Dermata Therapeutics, Inc.DRMA
| Dec 31, 2021 | Dec 31, 2022 |
---|
Net loss | -7,902,477 | -9,610,913 |
---|
Stock-based compensation | 2 | 930,325 |
---|
Amortization of debt discount costs | 14,126 | - |
---|
Prepaid expenses and other current assets | -750,081 | -121,940 |
---|
Accounts payable | 410,969 | -18,543 |
---|
Accrued and other current liabilities | 628,663 | -256,973 |
---|
Net cash used in operating activities: | -5,693,392 | -8,834,164 |
---|
Proceeds from issuance of common stock and warrants, net of issuance costs | - | 4 |
---|
Proceeds from issuances of common stock upon exercises of pre-funded warrants | - | 287 |
---|
Redemption of Series 1c preferred stock | 1,000,000 | - |
---|
Payments on debt | -556,482 | - |
---|
Net cash provided by financing activities: | 16 | 4 |
---|
Net increase (decrease) in cash and cash equivalents | - | -4,557,512 |
---|
Cash paid for taxes | 1,400 | 950 |
---|
Conversion of common and preferred units and warrants to common and preferred stock and warrants | 30 | - |
---|
Conversion of convertible subordinated promissory notes to Series 1d preferred units | 4 | - |
---|
Conversion of preferred stock to common stock at IPO | 6,582 | - |
---|